The advent of immune checkpoint inhibitors targeting the PD‐1 and PD‐L1 axes has transformed the first‐line management of advanced NSCLC [4, 5, 6, 7, 8]; however, critical questions persist regarding the comparative efficacy of PD‐1 and PD‐L1 inhibitors. Here, PDCD1 is linked to non-small cell lung carcinoma.